Opportunity Information: Apply for RFA DK 19 009
This NIH funding opportunity (RFA-DK-19-009) supports the continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) through awards to Clinical Centers (CCs) under a U01 cooperative agreement mechanism, with clinical trials listed as optional. The overall purpose is not to launch an entirely new program, but to sustain and complete the consortium's ongoing, coordinated clinical research portfolio that has been running since Fall 2015. The focus is on chronic pancreatitis (CP) across ages (children and adults), including patients with acute recurrent pancreatitis (ARP), and on identifying and clarifying factors that raise pancreatic cancer risk in key high-risk groups: people with CP, people with pancreatogenic diabetes (type 3c diabetes, T3cDM), and people with newly diagnosed diabetes. In practical terms, the FOA is aimed at keeping existing longitudinal studies moving forward, ensuring consistent participant characterization and biospecimen collection, and generating findings that improve understanding of disease mechanisms and cancer risk pathways.
Scientifically, the consortium's work centers on deep, longitudinal clinical phenotyping and biological characterization. It seeks to advance understanding of the pathophysiology of chronic pancreatitis and its major downstream complications, including chronic pain, pancreatic exocrine insufficiency, and the development of T3cDM. A major theme is the diabetes and pancreatic cancer association, including targeted work in individuals with newly diagnosed diabetes to better understand (and potentially detect) the subset of patients whose diabetes may be linked to underlying pancreatic cancer biology. By keeping studies harmonized across multiple clinical sites, the consortium is positioned to assemble larger, more diverse cohorts than any single center could, which is important for teasing apart heterogeneity in CP, ARP, diabetes subtypes, and cancer risk signals.
Structurally, the CPDPC is a multi-site network made up of several Clinical Centers plus a separate Coordination and Data Management Center (CDMC). This FOA is specifically for the Clinical Centers. The companion solicitation for the CDMC is RFA-DK-19-504, which covers the centralized coordinating, data, and management functions needed to run a consortium of this type. The expectation is that the CCs and CDMC operate as an integrated unit: clinical sites recruit and follow participants and generate high-quality clinical and biological data, while the coordinating center supports standardized operations, data harmonization, and cross-site analyses.
Because this is a cooperative agreement (U01), the program is meant to be highly collaborative and actively coordinated rather than a set of loosely related independent projects. Clinical Center applicants are expected to bring multidisciplinary teams with the expertise needed to contribute to the consortium's objectives and ongoing studies. That typically implies clinicians and investigators spanning pancreatology/gastroenterology, endocrinology/diabetes, oncology, genetics, epidemiology, biostatistics, imaging, pathology, and translational laboratory science, along with strong clinical research operations. The FOA emphasizes that participating centers should be able to align with the consortium's existing studies and procedures (referenced via the CPDPC clinical studies page) and contribute meaningfully to shared goals such as consistent cohort characterization and collaborative analyses.
A core expectation is open, timely sharing of results within the consortium and active participation in trans-consortium projects that leverage the combined expertise and technologies across sites. In other words, awardees are not just expected to enroll patients and publish locally; they are expected to work across centers, contribute data and specimens according to consortium standards, and help develop collaborative projects that use pooled resources to answer questions that require multi-site scale and coordination.
Eligibility is broad and includes many U.S.-based organizational types commonly eligible for NIH cooperative agreements, such as public and private institutions of higher education, nonprofits (with and without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, and multiple levels of government (state, county, city/township, special district). It also includes a number of specifically named institution types such as HBCUs, Hispanic-serving institutions, Tribally Controlled Colleges and Universities, and Alaska Native and Native Hawaiian Serving Institutions, among others. Foreign institutions (non-U.S. entities) are not eligible to apply as applicant organizations, but foreign components are allowed under NIH policy, and non-U.S. components of U.S. organizations may participate, which supports international collaboration when it adds value to the science and is structured in compliance with NIH rules.
Key administrative details from the source listing include the sponsoring agency (National Institutes of Health), the funding instrument (cooperative agreement), and the original closing date (2019-12-17). The opportunity is categorized under health-related CFDA numbers 93.393, 93.399, and 93.847. The listing does not specify an award ceiling or the expected number of awards in the provided excerpt, so applicants would need to consult the full FOA for budget limits, project periods, and the precise expectations for scope, milestones, and consortium participation requirements.Apply for RFA DK 19 009
- The National Institutes of Health in the education, food and nutrition, health sector is offering a public funding opportunity titled "Continuation of the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CPDPC-CCs) (U01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.399, 93.847.
- This funding opportunity was created on 2019-09-26.
- Applicants must submit their applications by 2019-12-17. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is this funding opportunity?
This is an NIH funding opportunity announcement (FOA) identified as RFA-DK-19-009. It supports awards to Clinical Centers (CCs) under a U01 cooperative agreement to continue the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC). Clinical trials are listed as optional under this opportunity.
What is the main goal of RFA-DK-19-009?
The purpose is to sustain and complete the CPDPC consortium's coordinated clinical research portfolio that has been operating since Fall 2015. It is not intended to start an entirely new program, but rather to keep existing longitudinal studies moving forward in a harmonized, multi-site way.
What diseases and populations are the focus of the consortium?
The scientific focus is chronic pancreatitis (CP) across ages, including both children and adults, and also includes patients with acute recurrent pancreatitis (ARP). Another major focus is identifying and clarifying factors that increase pancreatic cancer risk in key high-risk groups: people with CP, people with pancreatogenic diabetes (type 3c diabetes, T3cDM), and people with newly diagnosed diabetes.
Is this FOA meant to launch new studies or continue existing ones?
Based on the provided description, the FOA is aimed at continuing and completing ongoing, coordinated studies rather than launching an entirely new program. A practical emphasis is maintaining momentum in existing longitudinal studies and ensuring consistent procedures across sites.
What is meant by "deep, longitudinal clinical phenotyping and biological characterization" in this FOA?
In the context provided, it refers to comprehensive, repeated (longitudinal) collection of clinical information and biological data over time, with a focus on consistent participant characterization and biospecimen collection across consortium sites.
What downstream complications of chronic pancreatitis are specifically highlighted?
The consortium work is described as advancing understanding of CP pathophysiology and major downstream complications, including chronic pain, pancreatic exocrine insufficiency, and development of T3cDM (type 3c diabetes).
How does the FOA address the relationship between diabetes and pancreatic cancer?
A major theme is the diabetes and pancreatic cancer association, including targeted work in individuals with newly diagnosed diabetes. The goal described is to better understand the subset of patients whose diabetes may be linked to underlying pancreatic cancer biology, which can support improved understanding of cancer risk pathways.
Why is a multi-site consortium approach important for this research?
The consortium model is positioned to assemble larger and more diverse cohorts than any single center could. This scale is described as important for studying heterogeneity in chronic pancreatitis, acute recurrent pancreatitis, diabetes subtypes (including T3cDM), and pancreatic cancer risk signals.
What components make up the CPDPC network?
The CPDPC is described as a multi-site network consisting of multiple Clinical Centers (CCs) plus a separate Coordination and Data Management Center (CDMC).
Does RFA-DK-19-009 fund the Coordination and Data Management Center (CDMC)?
No. This FOA is specifically for Clinical Centers. The companion solicitation for the CDMC is RFA-DK-19-504, which covers centralized coordinating, data, and management functions.
How are responsibilities divided between Clinical Centers and the CDMC?
Clinical Centers are expected to recruit and follow participants and generate high-quality clinical and biological data. The CDMC supports standardized operations, data harmonization, and cross-site analyses so the consortium functions as an integrated unit.
What does it mean that this is a U01 cooperative agreement?
The provided description indicates the program is intended to be highly collaborative and actively coordinated, rather than a collection of loosely connected independent projects. Awardees are expected to participate in coordinated consortium activities and shared work, consistent with the cooperative agreement structure.
Are clinical trials required under this opportunity?
Clinical trials are described as optional for this FOA.
What types of expertise are expected on a Clinical Center team?
The FOA description emphasizes multidisciplinary teams. Examples of relevant expertise include pancreatology/gastroenterology, endocrinology/diabetes, oncology, genetics, epidemiology, biostatistics, imaging, pathology, translational laboratory science, and strong clinical research operations.
Do Clinical Center applicants need to follow existing consortium procedures?
Yes. Participating centers are expected to align with the consortium's existing studies and procedures (referenced via the CPDPC clinical studies page in the FOA description) and contribute to consistent cohort characterization and collaborative analyses.
What are expectations around data sharing and collaboration within the consortium?
A core expectation described is open, timely sharing of results within the consortium and active participation in trans-consortium projects that leverage combined expertise and technologies across sites. Awardees are expected to contribute data and specimens according to consortium standards and support collaborative, pooled analyses.
Who is eligible to apply as an applicant organization?
Eligibility is described as broad and includes many U.S.-based organizational types commonly eligible for NIH cooperative agreements. Examples provided include public and private institutions of higher education, nonprofits (with and without 501(c)(3) status), for-profit organizations (other than small businesses), small businesses, and state/county/city or township/special district governments. The description also names institution categories such as HBCUs, Hispanic-serving institutions, Tribally Controlled Colleges and Universities, and Alaska Native and Native Hawaiian Serving Institutions, among others.
Are foreign (non-U.S.) institutions eligible to apply as the main applicant?
No. Foreign institutions (non-U.S. entities) are not eligible to apply as applicant organizations under the description provided.
Can foreign components participate in projects funded by this FOA?
Yes. The description notes that foreign components are allowed under NIH policy, and non-U.S. components of U.S. organizations may participate, enabling international collaboration when it adds scientific value and follows NIH rules.
Which agency sponsors this funding opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
What is the funding instrument for this opportunity?
The funding instrument is a cooperative agreement.
What is the original closing date listed for this FOA?
The original closing date provided is 2019-12-17.
Which CFDA numbers are associated with this opportunity?
The opportunity is categorized under CFDA numbers 93.393, 93.399, and 93.847.
Does the provided listing include an award ceiling or expected number of awards?
No. The excerpt provided does not specify an award ceiling or the expected number of awards. Applicants are directed (in the description) to consult the full FOA for budget limits, project periods, and detailed expectations such as scope, milestones, and consortium participation requirements.
Browse more opportunities from the same category: Education, Food and Nutrition, Health
Next opportunity: The Physiology of the Weight Reduced State Data Coordinating Center (U24 Clinical Trial Not Allowed)
Previous opportunity: Pragmatic Trials of Managing Multimorbidity in Alzheimer's Disease (R61/R33 Clinical Trial Required)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA DK 19 009
Applicants also applied for:
Applicants who have applied for this opportunity (RFA DK 19 009) also looked into and applied for these:
| Funding Opportunity |
|---|
| HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional) Apply for PAR 20 030 Funding Number: PAR 20 030 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $150,000 |
| Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Biostatistics Research Center (BRC) (Collaborative U01 Clinical Trial Required) Apply for RFA DK 20 502 Funding Number: RFA DK 20 502 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Diabetes Prevention Program Outcomes Study (DPPOS) Clinical Centers (Collaborative U01 Clinical Trial Required) Apply for RFA DK 20 501 Funding Number: RFA DK 20 501 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Native American Research Centers for Health (NARCH) (S06 Clinical Trial Optional) Apply for PAR 20 125 Funding Number: PAR 20 125 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Development of Wearable Smart Devices for Continuous Monitoring of Circulating Nutrients, Metabolites and Hormones (R21/R33 Clinical Trial Required) Apply for PAR 20 134 Funding Number: PAR 20 134 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $200,000 |
| Martin Delaney Collaboratories for HIV Cure Research (UM1 Clinical Trial Not Allowed) Apply for RFA AI 20 035 Funding Number: RFA AI 20 035 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $3,500,000 |
| Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional) Apply for RFA OD 20 016 Funding Number: RFA OD 20 016 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Limited Competition: Lasker Clinical Research Scholars Transition Award (R00 Clinical Trial Optional) Apply for PAR 20 315 Funding Number: PAR 20 315 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional) Apply for PAR 21 068 Funding Number: PAR 21 068 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional) Apply for PAR 21 069 Funding Number: PAR 21 069 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $200,000 |
| Launching Future Leaders in Global Health (LAUNCH) Research Training Program (D43 Clinical Trial Optional) Apply for RFA TW 21 004 Funding Number: RFA TW 21 004 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional) Apply for PAR 21 246 Funding Number: PAR 21 246 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| HEAL Initiative: Advancing Health Equity in Pain Management (R61/R33 Clinical Trial Required) Apply for RFA NS 22 002 Funding Number: RFA NS 22 002 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Innovations for Healthy Living - Improving Minority Health and Eliminating Health Disparities (R43/R44 - Clinical Trial Optional) Apply for RFA MD 22 004 Funding Number: RFA MD 22 004 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Education Program on Translational Devices (R25 Clinical Trial Not Allowed) Apply for PAR 22 146 Funding Number: PAR 22 146 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $250,000 |
| Interventions that Address Structural Racism to Reduce Kidney Health Disparities - (U01 - Clinical Trial Required) Apply for RFA DK 22 014 Funding Number: RFA DK 22 014 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $500,000 |
| Interventions that Address Structural Racism to Reduce Kidney Health Disparities Research Coordinating Center (U24 - Clinical Trial Not Allowed) Apply for RFA DK 22 015 Funding Number: RFA DK 22 015 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: $500,000 |
| Interventions that Address Structural Racism to Reduce Kidney Health Disparities Research Coordinating Center (U24 - Clinical Trial Not Allowed) Apply for RFA DK 23 003 Funding Number: RFA DK 23 003 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Centers for AIDS Research (P30 Clinical Trial Not Allowed) Apply for PAR 23 116 Funding Number: PAR 23 116 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
| Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed) Apply for PAR 23 117 Funding Number: PAR 23 117 Agency: National Institutes of Health Category: Education, Food and Nutrition, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 19 009", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.